Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Katzelnick, D. J. Articles by Helstad, C. P. Search for Related Content PubMed Citation Articles by Katzelnick, D. J. Articles by Helstad, C. P. Other Delivery of Care Anxiety Disorders (General)

Impact of Generalized Social Anxiety Disorder in Managed Care

OBJECTIVE: The authors determined the costs associated with generalized social anxiety disorder in a managed care setting. METHOD: A three-phase mail and telephone survey was conducted from July to October 1998 in two outpatient clinics of a large health maintenance organization (HMO). The survey assessed direct costs, indirect costs, health-related quality of life, and clinical severity associated with generalized social anxiety disorder, both alone and with comorbid psychopathology. RESULTS: The weighted prevalence rate of current generalized social anxiety disorder was 8.2%. In the past year, only 0.5% of subjects with generalized social anxiety disorder had been accurately diagnosed. Yet 44.1% had a mental health specialty visit or had been prescribed an antidepressant, and psychiatric comorbidity was found in 43.6%. Noncomorbid generalized social anxiety disorder was associated with significantly lower health-related quality of life, work productivity, and earnings and greater utilization of health services; generalized social anxiety disorder with comorbid psychopathology was even more disabling. Suicide was attempted by 21.9% of subjects with noncomorbid generalized social anxiety disorder. Persons with average-severity generalized social anxiety disorder had probabilities of graduating from college that were 10 percentage points lower, earned wages that were 10% lower, and had probabilities of holding a technical, professional, or managerial job that were 14 percentage points lower than the comparison group. CONCLUSIONS: In a community cohort of HMO members, generalized social anxiety disorder was rarely diagnosed or treated despite being highly prevalent and associated with significant direct and indirect costs, comorbid depression, and impairment.

This article has been cited by other articles:

				K Poder, K Ghatavi, J. Fisk, T. Campbell, S Kisely, I Sarty, K Stadnyk, and V Bhan Social anxiety in a multiple sclerosis clinic population Multiple Sclerosis, March 1, 2009; 15(3): 393 - 398. [Abstract] [PDF]

				H. Delong and M. H. Pollack Update on the Assessment, Diagnosis, and Treatment of Individuals with Social Anxiety Disorder Focus, October 1, 2008; 6(4): 431 - 437. [Abstract] [Full Text] [PDF]

				Bibliography Panic and Social Anxiety Disorder Focus, October 1, 2008; 6(4): 459 - 461. [Full Text] [PDF]

				J. D. Ford, P. Stockton, S. Kaltman, and B. L. Green Disorders of Extreme Stress (DESNOS) Symptoms Are Associated With Type and Severity of Interpersonal Trauma Exposure in a Sample of Healthy Young Women J Interpers Violence, November 1, 2006; 21(11): 1399 - 1416. [Abstract] [PDF]

				F. R. Schneier Clinical practice. Social anxiety disorder. N. Engl. J. Med., September 7, 2006; 355(10): 1029 - 1036. [Full Text] [PDF]

				P. P. Roy-Byrne, M. G. Craske, M. B. Stein, G. Sullivan, A. Bystritsky, W. Katon, D. Golinelli, and C. D. Sherbourne A Randomized Effectiveness Trial of Cognitive-Behavioral Therapy and Medication for Primary Care Panic Disorder Arch Gen Psychiatry, March 1, 2005; 62(3): 290 - 298. [Abstract] [Full Text] [PDF]

				M. R. Liebowitz, A. J. Gelenberg, and D. Munjack Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder Arch Gen Psychiatry, February 1, 2005; 62(2): 190 - 198. [Abstract] [Full Text] [PDF]

				J. R. T. Davidson, E. B. Foa, J. D. Huppert, F. J. Keefe, M. E. Franklin, J. S. Compton, N. Zhao, K. M. Connor, T. R. Lynch, and K. M. Gadde Fluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placebo in Generalized Social Phobia Arch Gen Psychiatry, October 1, 2004; 61(10): 1005 - 1013. [Abstract] [Full Text] [PDF]

				S. Pallanti, L. Quercioli, and E. Hollander Social Anxiety in Outpatients With Schizophrenia: A Relevant Cause of Disability Am J Psychiatry, January 1, 2004; 161(1): 53 - 58. [Abstract] [Full Text] [PDF]

				R. D. Goodwin and J. M. Gorman Psychopharmacologic Treatment of Generalized Anxiety Disorder and the Risk of Major Depression Am J Psychiatry, November 1, 2002; 159(11): 1935 - 1937. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us